NCT03744468: Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors

NCT03744468
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with active brain or leptomeningeal metastasis; Patients who have received prior therapies targeting TIM-3
https://ClinicalTrials.gov/show/NCT03744468

Comments are closed.

Up ↑